Enzyme mutant, enzyme composition or immobilized enzyme thereof, and application and method for preparing cordycepin by using enzyme mutant or immobilized enzyme thereof

By developing mutant enzymes and ATP/NADH regeneration systems, the biosynthesis route of Cordycepsin has been simplified, the problems of high preparation costs and difficulty in heterologous expression of enzymes in the prior art are solved, and efficient and inexpensive Cordycepsin production are achieved.

CN118931867AActive Publication Date: 2024-11-12SOUTH CHINA NORMAL UNIV
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202410990709.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-12
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

The existing preparation methods of cordyceps sinensis have problems such as high preparation cost, high pollution, limited scale, cumbersome chemical synthesis steps and low yields. Especially the solubility problems of enzymes when heterologously expressed, making it difficult to achieve industrial production.

Method used

By developing mutants of Cordyceps kinase, dephosphatase, reductase and pyruvate kinase with industrial properties, combined with ATP and NADH regeneration systems, the homozygous synthesis of Cordyceps simplifies the biosynthesis route and improves the conversion rate.

Benefits of technology

It realizes efficient and simple biosynthesis of Cordyceps sinensis, reduces production costs, has the advantages of green, cheap and easy to scale, and solves the solubility problem in heterologous expression of enzymes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004958914370000091
    Figure BDA0004958914370000091
  • Figure BDA0004958914370000101
    Figure BDA0004958914370000101
  • Figure BDA0004958914370000111
    Figure BDA0004958914370000111
Patent Text Reader

Abstract

The invention relates to the field of enzyme engineering, in particular to an enzyme mutant, an enzyme composition or an immobilized enzyme thereof, and application and a method for preparing cordycepin by using the enzyme mutant and the enzyme composition. According to the method, Adenosine is used as an initial raw material, 3 '-adenosine monophosphate (3'-AMP) is generated under the action of adenosine 3 '-kinase (Cor3K), then dehydrated adenosine is generated by using cordycepin dephosphatase (CorDep), and finally cordycepin is generated under the conversion of cordycepin reductase (CorRed). The route is very simple, the conversion rate is high, and the used raw materials are very cheap. The conversion can be completed step by step and can also be completed at a time through a one-pot method. Meanwhile, pyruvate kinase (PcPyk) and formate dehydrogenase (MspFDH) can be introduced into coenzymes ATP and NADH required by conversion in the first step and the third step for cyclic regeneration, so that the production price of the coenzymes is further reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of enzyme engineering, and in particular to an enzyme mutant, an enzyme composition or an immobilized enzyme thereof, and an application and method for preparing cordycepin. Background Art

[0002] Cordycepin is also known as cordyceps sinensis, cordycepin, and cordycepin. Its alias is 3'-deoxyadenosine, and its chemical formula is C 10 H 13 N5O3 is the first nucleoside antibiotic isolated from fungi. It has a long history of application and has multiple pharmacological activities such as antibacterial, anti-inflammatory, antiviral, anti-tumor and immunomodulatory. Phase III clinical trial data also show that cordycepin can be used to treat patients with acute pre-B and pre-T lymphocytic leukemia. In recent years, biological research has further found that cordycepin can enhance human immunity and clear the increase of free radicals in the body caused by human aging.

[0003] At present, cordycepin is mainly obtained by extraction and separation from artificially cultivated Cordyceps militaris, which has high preparation cost, high price, large pollution and limited scale. The chemical synthesis method uses adenosine as raw material and obtains it through multi-step group protection operation, free radical reduction and then deprotection; the entire synthesis process is cumbersome, the yield is low and the production price is expensive.

[0004] Cordycepin is a natural compound. Its biological preparation has the advantages of environmental compatibility, high product quality and low price. The biosynthesis of cordycepin has been reported for a long time. The raw material adenosine is phosphorylated under the action of cns3 kinase to obtain 3'-adenosine phosphate (3'-AMP), and then dephosphorylated under the action of cns2 enzyme to obtain 2'-glycosyl-3'-deoxyadenosine, and finally 3'-deoxyadenosine (cordycepin) is generated under the action of cns1 ketoreductase. However, the enzymes of this synthetic pathway are only distributed in a few fungi, and there are solubility problems when they are heterologously expressed in industrial bacteria.

[0005] Therefore, providing a biological method for preparing cordycepin has important practical significance. Summary of the invention

[0006] In view of this, in order to solve the above problems, through long-term laboratory testing and research, we finally obtained cns3 and cns1 replacement enzymes with industrial performance, and then combined with the adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide (NADH) regeneration systems commonly used in enzyme catalysis applications, so as to achieve cordycepin holoenzyme synthesis.

[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0008] In a first aspect, the present invention provides a mutant of an enzyme, wherein the enzyme comprises one or more of cordycepin kinase (Cor3K), cordycepin dephosphatase (CorDep), cordycepin reductase (CorRed), pyruvate kinase (PcPyK) and / or formate dehydrogenase (MspFDH);

[0009] The mutation site of the cordycepin kinase (Cor3K) includes one or more of R13A, M14L, W32T, G35F, D63S, G64M, D65Q, R68I, G70M, N72Y, N73K, I89V, Q157T or K180S;

[0010] The mutation site of the cordycepin dephosphatase (CorDep) includes one or more of K130N, E149D or A175V;

[0011] The mutation site of the cordycepin reductase (CorRed) includes one or more of S68M, E69G, E70F, R81V, K89S, P92W, F127N, G128I, T133V, R184A, H187T or N198D;

[0012] The mutation site of the pyruvate kinase (PcPyK) includes one or more of F31I, P99N, G105L, P169M, D248T or W312F;

[0013] The mutation sites of the formate dehydrogenase (MspFDH) include one or more of P12C, Q35T or Y188L.

[0014] In some specific embodiments of the present invention, in the mutant of the enzyme, the cordycepin kinase (Cor3K) is derived from Bacteroides thetaiotaomicron (Uniprot ID: Q8AAQ1, EC 2.7.1.25);

[0015] The cordycepin dephosphatase (CorDep) is derived from Cordyceps militaris (UniprotID: G3JF09);

[0016] The cordycepin reductase (CorRed) is derived from Thermococcus sibiricus (Uniprot ID: C6A1Z0);

[0017] The pyruvate kinase (PcPyK) is derived from Pyrobaculum calidifontis (Uniprot ID: A3MS52, EC 2.7.1.40);

[0018] The formate dehydrogenase (MspFDH) is derived from Microbacterium sp.

[0019] In some specific embodiments of the present invention, the mutants of the enzyme include mutants of cordycepin kinase (Cor3K), mutants of cordycepin dephosphatase (CorDep), mutants of cordycepin reductase (CorRed), mutants of pyruvate kinase (PcPyK) and / or mutants of formate dehydrogenase (MspFDH);

[0020] Wherein, the mutant of cordycepin kinase (Cor3K) has:

[0021] (I), the amino acid sequence shown in SEQ ID No.1;

[0022] (II) an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence described in (I), and having the same function as the amino acid sequence described in (I); or

[0023] (III), an amino acid sequence having 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or more identity with the amino acid sequence described in (I) or (II); or

[0024] The mutant of cordycepin dephosphatase (CorDep) has:

[0025] (I), the amino acid sequence shown in SEQ ID No.2;

[0026] (II) an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence described in (I), and having the same function as the amino acid sequence described in (I); or

[0027] (III), an amino acid sequence having 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or more identity with the amino acid sequence described in (I) or (II); or

[0028] The mutant of cordycepin reductase (CorRed) has:

[0029] (I), the amino acid sequence shown in SEQ ID No.3;

[0030] (II) an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence described in (I), and having the same function as the amino acid sequence described in (I); or

[0031] (III), an amino acid sequence having 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or more identity with the amino acid sequence described in (I) or (II); or

[0032] The mutant of pyruvate kinase (PcPyK) has:

[0033] (I), the amino acid sequence shown in SEQ ID No.4;

[0034] (II) an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence described in (I), and having the same function as the amino acid sequence described in (I); or

[0035] (III), an amino acid sequence having 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or more identity with the amino acid sequence described in (I) or (II); or

[0036] The mutant of formate dehydrogenase (MspFDH) has:

[0037] (I), the amino acid sequence shown in SEQ ID No.5;

[0038] (II) an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence described in (I), and having the same function as the amino acid sequence described in (I); or

[0039] (III) an amino acid sequence that is 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% or more identical to the amino acid sequence described in (I) or (II).

[0040] In a second aspect, the present invention also provides an enzyme composition or an immobilized enzyme thereof, including a mutant of the enzyme.

[0041] In a third aspect, the present invention also provides a nucleic acid molecule encoding a mutant of the enzyme or the enzyme composition or an immobilized enzyme thereof.

[0042] In some specific embodiments of the present invention, the nucleic acid molecules include nucleic acid molecules encoding mutants of the cordycepin kinase (Cor3K), nucleic acid molecules encoding mutants of the cordycepin dephosphatase (CorDep), nucleic acid molecules encoding mutants of the cordycepin reductase (CorRed), nucleic acid molecules encoding mutants of the pyruvate kinase (PcPyK) and / or nucleic acid molecules encoding mutants of the formate dehydrogenase (MspFDH);

[0043] The nucleic acid molecule encoding the mutant of cordycepin kinase (Cor3K) has:

[0044] (I), the nucleotide sequence shown in SEQ ID NO.6; or

[0045] (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or

[0046] (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or

[0047] (IV), a nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to any one of (I) to (III); or

[0048] The nucleic acid molecule encoding the mutant of cordycepin dephosphatase (CorDep) has:

[0049] (I), the nucleotide sequence shown in SEQ ID NO.7; or

[0050] (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or

[0051] (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or

[0052] (IV), a nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to any one of (I) to (III); or

[0053] The nucleic acid molecule encoding the mutant of cordycepin reductase (CorRed) has:

[0054] (I), the nucleotide sequence shown in SEQ ID NO.8; or

[0055] (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or

[0056] (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or

[0057] (IV), a nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to any one of (I) to (III); or

[0058] The nucleic acid molecule encoding the mutant of pyruvate kinase (PcPyK) has:

[0059] (I), the nucleotide sequence shown in SEQ ID NO.9; or

[0060] (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or

[0061] (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or

[0062] (IV), a nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to any one of (I) to (III); or

[0063] The nucleic acid molecule encoding the mutant of formate dehydrogenase (MspFDH) has:

[0064] (I), the nucleotide sequence shown in SEQ ID NO.10; or

[0065] (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or

[0066] (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or

[0067] (IV) A nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to any one of the nucleotide sequences of (I) to (III).

[0068] In a fourth aspect, the present invention further provides an expression vector or a host, wherein the expression vector comprises the nucleic acid molecule;

[0069] The host is transfected or transformed with the expression vector.

[0070] In a fifth aspect, the present invention further provides the use of any of the following items in the preparation of cordycepin:

[0071] (I), a mutant of the enzyme;

[0072] (II), the enzyme composition or the immobilized enzyme thereof;

[0073] (III), the nucleic acid molecule; or

[0074] (IV), the expression vector or host.

[0075] In a sixth aspect, the present invention also provides a method for preparing cordycepin, using adenosine as a raw material, and converting cordycepin by any of the following steps:

[0076] (I), a mutant of the enzyme;

[0077] (II), the enzyme composition or the immobilized enzyme thereof;

[0078] (III), the nucleic acid molecule; or

[0079] (IV), the expression vector or host.

[0080] In some specific embodiments of the present invention, the preparation method is specifically, using adenosine as a starting material, generating 3'-adenosine phosphate (3'-AMP) under the action of the mutant of the cordycepin kinase (Cor3K), then generating dehydrated adenosine using the mutant of the cordycepin dephosphatase (CorDep), and finally generating cordycepin under the transformation of the mutant of the cordycepin reductase (CorRed);

[0081] The enzyme activity of the mutant of cordycepin kinase (Cor3K) is 800-1500, 1200-2000 U or 1400-1600 U; or

[0082] The enzymatic activity of the mutant of cordycepin dephosphatase (CorDep) is 1200-1800U, 1800-2400U or 800-1200U; or

[0083] The enzyme activity of the mutant of cordycepin reductase (CorRed) is 800-1200U, 1500-2200U or 900-1100U; or

[0084] The enzyme activity of the mutant of pyruvate kinase (PcPyK) is 1800-3000U or 1800-2400U; or

[0085] The enzyme activity of the mutant of formate dehydrogenase (MspFDH) is 2800-3500 or 1800-2400U.

[0086] In some specific embodiments of the present invention, the ratio of the raw material to the enzyme mutant is:

[0087] Adenosine: adenosine triphosphate disodium salt: the mutant of cordycepin kinase (Cor3K) = 100 mM: (90-120 mM): (800-1500 U).

[0088] In some specific embodiments of the present invention, the ratio of the raw material to the enzyme mutant is:

[0089] Adenosine: adenosine triphosphate disodium salt: phosphoenolpyruvate (PEP): the mutant of the cordycepin kinase (Cor3K): the mutant of the pyruvate kinase (PcPyK) = 200mM: (5-20mM): (180-250mM): (1200-2000U): (1800-3000U).

[0090] In some specific embodiments of the present invention, the ratio of the raw material to the enzyme mutant is:

[0091] 3'-adenosine disodium salt: reduced nicotinamide adenine dinucleotide disodium salt (NADH): the mutant of the cordycepin dephosphatase (CorDep): the mutant of the cordycepin reductase (CorRed) = 100 mM: (80-120 mM): (1200-1800 U): (800-1200 U).

[0092] In some specific embodiments of the present invention, the ratio of the raw material to the enzyme mutant is:

[0093] 3'-adenosine phosphate disodium salt: reduced nicotinamide adenine dinucleotide disodium salt (NADH): the mutant of the cordycepin dephosphatase (CorDep): the mutant of the cordycepin reductase (CorRed): the mutant of the formate dehydrogenase (MspFDH) = 150 mM: (2-6 mM):

[0094] (1800~2400U): (1500~2200U): (2800~3500U).

[0095] In some specific embodiments of the present invention, cordycepin is prepared in one pot using adenosine as raw material and liquid enzymes (Cor3K, CorDep, CorRed) and ATP regenerating enzyme (PcPyK) and NADH regenerating enzyme (MspFDH).

[0096] The ratio of raw material to enzyme mutant is:

[0097] Adenosine: adenosine triphosphate disodium salt: phosphoenolpyruvate: reduced nicotinamide adenine dinucleotide disodium salt (NADH): the mutant of the cordycepin kinase (Cor3K): the mutant of the cordycepin dephosphatase (CorDep): the mutant of the cordycepin reductase (CorRed): the mutant of the pyruvate kinase (PcPyK): the mutant of the formate dehydrogenase (MspFDH) = 100mM: (2.0~6.0mM): (90~130mM): (3.0~6.0mM): (1400~1600U): (1800~2400U): (800~1200U): (900~1100U): (1800~2400U).

[0098] The present invention provides a full bioconversion of cordycepin. The overall process is to use adenosine as a starting material, generate 3'-adenosine phosphate (3'-AMP) under the action of adenosine 3'-kinase (Cor3K), then generate dehydrated adenosine using cordycepin dephosphatase (CorDep), and finally generate cordycepin under the conversion of cordycepin reductase (CorRed). The route is very simple, the conversion rate is high, and the raw materials used are also very cheap. This conversion can be completed step by step or in one pot. At the same time, for the coenzymes ATP and NADH required for the first and third steps of the conversion, pyruvate kinase (PcPyk) and formate dehydrogenase (MspFDH) can also be introduced for recycling, thereby further reducing its production price. Therefore, the patented synthetic cordycepin preparation process has many advantages such as green, cheap, and easy to scale. BRIEF DESCRIPTION OF THE DRAWINGS

[0099] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.

[0100] Figure 1 The SDS-PAGE gel detection diagram of the enzyme prepared by the present invention is shown;

[0101] Figure 2 1H-NMR of cordycepin, D2O as solvent, Varian 600 MHz NMR. DETAILED DESCRIPTION

[0102] The present invention discloses enzyme mutants, enzyme compositions or immobilized enzymes thereof and their applications and methods for preparing cordycepin. Those skilled in the art can refer to the contents of this article and appropriately improve the process parameters for implementation. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0103] The present invention provides a full bioconversion of cordycepin. The overall process is to use adenosine as a starting material, generate 3'-adenosine phosphate (3'-AMP) under the action of adenosine 3'-kinase (Cor3K), then generate dehydrated adenosine using cordycepin dephosphatase (CorDep), and finally generate cordycepin under the conversion of cordycepin reductase (CorRed). The route is very simple, the conversion rate is high, and the raw materials used are also very cheap. This conversion can be completed step by step or in one pot. At the same time, for the coenzymes ATP and NADH required for the first and third steps of the conversion, pyruvate kinase (PcPyk) and formate dehydrogenase (MspFDH) can also be introduced for recycling, thereby further reducing its production price. Therefore, the patented synthetic cordycepin preparation process has many advantages such as green, cheap, and easy to scale.

[0104]

[0105] Information about the enzymes used above:

[0106] Table 1

[0107] English abbreviations English full name Chinese meaning Cor3K Cordycepin kinase Cordycepin kinase CorDep Cordycepin Dephosphatase Cordycepin dephosphatase CorRed Cordycepin Reductase Cordycepin reductase PcqI Pc Pyruvate Kinase Crenarchaea pyruvate kinase MspFDH Ms Formate dehydrogenase Microbacterium formate oxidase

[0108] Cordycepin kinase (Cor3K): derived from Bacteroides thetaiotaomicron (Uniprot ID: Q8AAQ1, EC 2.7.1.25), the original active substrate of the natural enzyme (WTCor3K) is adenylate sulfate, and it also has weak cordycepin kinase activity; after systematic mutation modification (Cor3K), it has high cordycepin kinase activity, and its mutation sites are: R13A, M14L, W32T, G35F, D63S, G64M, D65Q, R68I, G70M, N72Y, N73K, I89V, Q157T, K180S;

[0109] Cordycepin dephosphatase (CorDep): derived from Cordyceps militaris (Uniprot ID: G3JF09), the natural enzyme (WTCorDep) itself has this activity, and the expression and stability of the enzyme are improved through certain mutation modification (CorDep); the mutation sites are: K130N, E149D, A175V;

[0110] Cordycepin reductase (CorRed): Derived from Thermococcus sibiricus (Uniprot ID: C6A1Z0), the natural enzyme (WTCorRed) has a weak ability to reduce cordycepin, but its expression and activity are significantly improved through a large number of mutations (CorRed); its mutation sites are: S68M, E69G, E70F, R81V, K89S, P92W, F127N, G128I, T133V, R184A, H187T, N198D.

[0111] Pyruvate kinase PcPyK: Derived from Pyrobaculum calidifontis (Uniprot ID: A3MS52, EC 2.7.1.40), the natural enzyme (WTPcPyK) can effectively use phosphoenolpyruvate (PEP) to regenerate adenosine triphosphate (ATP), but its expression and stability are poor. Through transformation and screening (PcPyK), an enzyme with superior performance was finally obtained. Its specific mutation sites are: F31I, P99N, G105L, P169M, D248T, W312F.

[0112] Formate dehydrogenase (MspFDH): Derived from Microbacterium sp., this natural enzyme (WTMspFDH) can effectively utilize formate to regenerate NADH (Uniprot ID: A0A0P0DRT5, EC 1.17.1.9). In order to further improve its expression and stability, it has been modified (MspFDH), and its mutation sites are: P12C, Q35T, Y188L.

[0113] Table 2

[0114]

[0115]

[0116] Table 3

[0117]

[0118]

[0119]

[0120]

[0121] In the enzyme mutant, enzyme composition or immobilized enzyme thereof and the application and method for preparing cordycepin provided by the present invention, the raw materials and reagents used can be purchased from the market.

[0122] The present invention will be further described below in conjunction with embodiments:

[0123] Preparation Example 1 Fermentation production of enzyme:

[0124] The enzymes used in this patent are all produced by laboratory fermentation. The following is the basic operation process for preparing the enzyme. First, the gene sequence corresponding to the enzyme is synthesized by a gene company (Anhui General Biotechnology), and then subcloned into the pET28a plasmid through the NdeI / XhoI restriction site, and the plasmid is transferred into E. coli (BL21) (Qingke Biology) cells for plate culture, and finally a single clone is selected for liquid step-by-step amplification culture. The following is the basic process of step-by-step cell amplification culture. First, the single colony on the plate is transferred into 5ml LB culture medium containing 50μM kanamycin (37℃) for culture. When the cells grow to the logarithmic phase, they are inoculated into 250ml LB culture medium containing the same antibiotics, and finally transferred to a 5L culture fermenter for culture; when the cell OD is ~20, 0.5mM isopropyl-β-D-thiogalactopyranoside (IPTG) is added at 25℃ to induce protein expression for 8 hours, and then centrifuged (4000rpm, 15min) to collect 30-50g of wet cells. To verify the expression of the enzyme, first take a small amount of cells and mix them evenly with Tris.HCl buffer (50mM, pH 8.0), then use the freeze-thaw method to break the cells, take the supernatant after high-speed centrifugation and run SDS-PAGE protein gel (sodium dodecyl sulfate-polyacrylamide gel) to determine the soluble expression of the protein; confirm that the remaining cells are correct and mix them with buffer (10 grams of wet cells are mixed with about 200ml of marketed buffer), then high-pressure cell breaking and high-speed centrifugation (16000rpm, 45min) are performed to remove the cell wall, and the enzyme-containing clear liquid obtained is directly used in the subsequent use (the liquid enzyme activity is 220-500U / ml, U is the amount of enzyme required to convert 1μmol of substrate in one minute at room temperature) or further purified and immobilized for use (for solid enzyme reaction). LB medium consists of: 1% tryptone, 0.5% yeast powder, 1% NaCl, 1% dipotassium hydrogen phosphate, 1% dipotassium hydrogen phosphate and 5% glycerol.

[0125] Table 4 Summary of enzyme properties involved in this patent

[0126]

[0127] Example 1 Preparation of 3'-adenosine phosphate by liquid enzyme (Cor3K) using adenosine as raw material

[0128]

[0129] 26.7 g of adenosine (100 mM), 2.1 g of magnesium chloride hexahydrate (10 mM), 1.5 g of potassium chloride (20 mM) and 60.8 g of adenosine triphosphate disodium salt (110 mM) were added to 1 L of 50 mM pH 8.0 tris-hydroxymethylaminomethane hydrochloric acid (Tris.HCl) solution, and then the reaction solution was adjusted back to pH 8.0 using 0.1 N sodium hydroxide aqueous solution. Finally, 1000 U of Cor3K crude enzyme solution was added to start the reaction. During the reaction, sodium hydroxide aqueous solution was continuously added to maintain the pH between 7.0 and 8.5. The reaction was basically completed after 3 hours. A dilute HCl aqueous solution was added to adjust the pH value of the reaction solution to 2.0 to denature Cor3K and terminate the reaction. The pH value was then adjusted back to 7.0 and D201 anion exchange resin (Tianjin Yunkai Resin Technology Co., Ltd.) was used to separate the product 3'-adenosine phosphate and the impurity adenosine diphosphate ADP. Finally, a reverse osmosis membrane was used to desalt and concentrate to obtain 36 g of crude 3'-adenosine disodium phosphate (off-white solid, yield 92%, the solid can be directly used for the next step reaction without purification).

[0130] Example 2 Preparation of 3'-adenosine phosphate by liquid enzyme (Cor3K) using adenosine as raw material

[0131]

[0132] 26.7 g of adenosine (100 mM), 2.1 g of magnesium chloride hexahydrate (10 mM), 1.5 g of potassium chloride (20 mM) and 49.7 g of adenosine triphosphate disodium salt (90 mM) were added to 1 L of 50 mM pH 8.0 tris-hydroxymethylaminomethane hydrochloric acid (Tris.HCl) solution, and then the reaction solution was adjusted back to pH 8.0 using 0.1 N sodium hydroxide aqueous solution. Finally, 800 U of Cor3K crude enzyme solution was added to start the reaction. During the reaction, sodium hydroxide aqueous solution was continuously added to maintain the pH between 7.0 and 8.5. The reaction was basically completed after 3 hours. A dilute HCl aqueous solution was added to adjust the pH value of the reaction solution to 2.0 to denature Cor3K and terminate the reaction. The pH value was then adjusted back to 7.0 and D201 anion exchange resin (Tianjin Yunkai Resin Technology Co., Ltd.) was used to separate the product 3'-adenosine phosphate and the impurity adenosine diphosphate ADP. Finally, a reverse osmosis membrane was used to desalt and concentrate to obtain 34.8 g of crude 3'-adenosine disodium phosphate (off-white solid, yield 89%, the solid can be directly used for the next step reaction without purification).

[0133] Example 3 Preparation of 3'-adenosine phosphate by liquid enzyme (Cor3K) using adenosine as raw material

[0134]

[0135] 26.7 g of adenosine (100 mM), 2.1 g of magnesium chloride hexahydrate (10 mM), 1.5 g of potassium chloride (20 mM) and 66.3 g of adenosine triphosphate disodium salt (120 mM) were added to 1 L of 50 mM pH 8.0 tris-hydroxymethylaminomethane hydrochloric acid (Tris.HCl) solution, and then the reaction solution was adjusted back to pH 8.0 using 0.1 N sodium hydroxide aqueous solution. Finally, 1500 U of Cor3K crude enzyme solution was added to start the reaction. During the reaction, sodium hydroxide aqueous solution was continuously added to maintain the pH between 7.0 and 8.5. The reaction was basically completed after 3 hours. A dilute HCl aqueous solution was added to adjust the pH value of the reaction solution to 2.0 to denature Cor3K and terminate the reaction. The pH value was then adjusted back to 7.0 and D201 anion exchange resin (Tianjin Yunkai Resin Technology Co., Ltd.) was used to separate the product 3'-adenosine phosphate and the impurity adenosine diphosphate ADP. Finally, a reverse osmosis membrane was used to desalt and concentrate to obtain 36.8 g of crude 3'-adenosine disodium phosphate (off-white solid, yield 94%, the solid can be directly used for the next step reaction without purification).

[0136] Example 4 Preparation of 3'-adenosine phosphate using adenosine as raw material, liquid enzyme (Cor3K) and ATP regenerating enzyme (PcPyK)

[0137]

[0138] Similar to Example 1, 53.4 g of adenosine (200 mM), 4.2 g of magnesium chloride hexahydrate (20 mM), 3.8 g of potassium chloride (50 mM), 5.5 g of adenosine triphosphate disodium salt (10 mM) and 39.9 g of phosphoenolpyruvate (PEP, 210 mM) were added to 1 L of 50 mM pH 8.0 tris(hydroxymethylaminomethane) hydrochloric acid (Tris.HCl) solution. Then, the reaction solution was adjusted back to pH 8.0 using 0.1 N sodium hydroxide aqueous solution. Finally, 1500 U of Cor3K crude enzyme solution and 2000 U of PcPyK crude enzyme solution were added to start the reaction. During the reaction, sodium hydroxide aqueous solution was continuously added to maintain the pH between 7.0 and 8.5. After 4 hours, the reaction was basically completed. A dilute HCl aqueous solution was added to adjust the pH value of the reaction solution to 2.0 to denature the Cor3K and PcPyK enzymes to terminate the reaction, and then the pH value was adjusted back to 7.0. 54 barium oxalate (240 mM) was added to the reaction solution to precipitate the phosphoric acid-containing compound, and then the precipitated solid was collected by centrifugation and dissolved in a pH 1.0 HCl aqueous solution. 35.5 g of anhydrous sodium sulfate (250 mM) was added to precipitate the barium ions in the solution, and the solid BaSO4 was removed by centrifugation. Finally, the pH value of the solution was adjusted back to 7.0, and then the solution was desalted using a reverse osmosis membrane and concentrated to obtain 68 g of 3'-adenosine disodium phosphate (white solid, yield 87%, the solid can be directly used for the next step reaction without purification). Example 5 Preparation of 3'-adenosine phosphate using adenosine as a raw material, liquid enzyme (Cor3K) and ATP regeneration enzyme (PcPyK)

[0139]

[0140] Similar to Example 2, 53.4 g of adenosine (200 mM), 4.2 g of magnesium chloride hexahydrate (20 mM), 3.8 g of potassium chloride (50 mM), 2.8 g of adenosine triphosphate disodium salt (5 mM) and 34.2 g of phosphoenolpyruvate (PEP, 180 mM) were added to 1 L of 50 mM pH 8.0 trishydroxymethylaminomethane hydrochloric acid (Tris.HCl) solution. Then, the reaction solution was adjusted back to pH 8.0 using 0.1 N sodium hydroxide aqueous solution. Finally, 1200 U of Cor3K crude enzyme solution and 1800 U of PcPyK crude enzyme solution were added to start the reaction. During the reaction, sodium hydroxide aqueous solution was continuously added to maintain the pH between 7.0 and 8.5. After 4 hours, the reaction was basically completed. A dilute HCl aqueous solution was added to adjust the pH value of the reaction solution to 2.0 to denature the Cor3K and PcPyK enzymes to terminate the reaction, and then the pH value was adjusted back to 7.0. 54 g of barium oxalate (240 mM) was added to the reaction solution to precipitate the phosphoric acid compound, and then the precipitated solid was collected by centrifugation and dissolved in a pH 1.0 HCl aqueous solution. 28.4 g of anhydrous sodium sulfate (200 mM) was added to precipitate the barium ions in the solution, and the solid BaSO4 was removed by centrifugation. Finally, the pH value of the solution was adjusted back to 7.0, and then the solution was desalted by a reverse osmosis membrane and concentrated to obtain 64 g of 3'-adenosine disodium phosphate (white solid, yield 82%, the solid can be directly used for the next step without purification).

[0141] Example 6 Preparation of 3'-adenosine phosphate using adenosine as raw material, liquid enzyme (Cor3K) and ATP regenerating enzyme (PcPyK)

[0142]

[0143] Similar to Example 3, 53.4 g of adenosine (200 mM), 4.2 g of magnesium chloride hexahydrate (20 mM), 3.8 g of potassium chloride (50 mM), 11 g of adenosine triphosphate disodium salt (20 mM) and 47.5 g of phosphoenolpyruvate (PEP, 250 mM) were added to 1 L of 50 mM pH 8.0 trishydroxymethylaminomethane hydrochloric acid (Tris.HCl) solution. Then, the reaction solution was adjusted back to pH 8.0 using 0.1 N sodium hydroxide aqueous solution. Finally, 2000 U of Cor3K crude enzyme solution and 3000 U of PcPyK crude enzyme solution were added to start the reaction. During the reaction, sodium hydroxide aqueous solution was continuously added to maintain the pH between 7.0 and 8.5. After 4 hours, the reaction was basically completed. A dilute HCl aqueous solution was added to adjust the pH value of the reaction solution to 2.0 to denature the Cor3K and PcPyK enzymes to terminate the reaction, and then the pH value was adjusted back to 7.0. 54 barium oxalate (240 mM) was added to the reaction solution to precipitate the phosphoric acid compound, and then the precipitated solid was collected by centrifugation and dissolved in a pH 1.0 HCl aqueous solution. 42.6 g of anhydrous sodium sulfate (300 mM) was added to precipitate the barium ions in the solution, and the solid BaSO4 was removed by centrifugation. Finally, the pH value of the solution was adjusted back to 7.0, and then the solution was desalted by a reverse osmosis membrane and concentrated to obtain 70 g of 3'-adenosine disodium phosphate (white solid, yield 90%, the solid can be directly used for the next step without purification).

[0144] Example 7 Preparation of cordycepin using liquid enzymes (CorDep, CorRed) using 3'-adenosine phosphate as raw material

[0145]

[0146] 39.1 g of 3'-adenosine disodium phosphate (100 mM) and 78.1 g of reduced nicotinamide adenine dinucleotide disodium salt (NADH, 110 mM) were added to 1 L 100 mM pH 7.0 tris(hydroxymethylaminomethane) hydrochloric acid (Tris.HCl) solution, and then the reaction solution was adjusted back to pH 7.0. Finally, 1500 U CorDep crude enzyme solution and 1000 U CorRed crude enzyme solution were added to start the reaction. During the reaction, the reaction pH was adjusted between 6.5 and 8.0. The reaction was completed after 3 hours. The pH value of the reaction solution was adjusted to acidity to terminate the reaction, and then the pH value of the solution was adjusted back to 7.0. D201 anion exchange resin was loaded to remove phosphoric acid impurities. Finally, the cordycepin solution was desalted, concentrated and crystallized using a reverse osmosis membrane (ethanol: water, 2:1, v:v) to obtain 20.8 g of cordycepin (white solid, yield 83%).

[0147] Example 8 Preparation of cordycepin using liquid enzymes (CorDep, CorRed) using 3'-adenosine phosphate as raw material

[0148]

[0149] 39.1 g of 3'-adenosine disodium phosphate (100 mM) and 56.8 g of reduced nicotinamide adenine dinucleotide disodium salt (NADH, 80 mM) were added to 1 L 100 mM pH 7.0 tris(hydroxymethylaminomethane) hydrochloric acid (Tris.HCl) solution, and then the reaction solution was adjusted back to pH 7.0. Finally, 1200 U CorDep crude enzyme solution and 800 U CorRed crude enzyme solution were added to start the reaction. During the reaction, the reaction pH was adjusted between 6.5 and 8.0. The reaction was completed after 3 hours. The pH value of the reaction solution was adjusted to acidity to terminate the reaction, and then the pH value of the solution was adjusted back to 7.0 and D201 anion exchange resin was loaded to remove phosphoric acid impurities. Finally, the cordycepin solution was desalted, concentrated and crystallized using a reverse osmosis membrane (ethanol: water, 2:1, v:v) to obtain 19.5 g of cordycepin (white solid, yield 75%).

[0150] Example 9 Preparation of cordycepin using liquid enzymes (CorDep, CorRed) using 3'-adenosine phosphate as raw material

[0151]

[0152] 39.1 g of 3'-adenosine disodium phosphate (100 mM) and 85.2 g of reduced nicotinamide adenine dinucleotide disodium salt (NADH, 120 mM) were added to 1 L 100 mM pH 7.0 tris(hydroxymethylaminomethane) hydrochloric acid (Tris.HCl) solution, and then the reaction solution was adjusted back to pH 7.0. Finally, 1800 U CorDep crude enzyme solution and 1200 U CorRed crude enzyme solution were added to start the reaction. During the reaction, the reaction pH was adjusted between 6.5 and 8.0. The reaction was completed after 3 hours. The pH value of the reaction solution was adjusted to acidity to terminate the reaction, and then the pH value of the solution was adjusted back to 7.0. D201 anion exchange resin was loaded to remove phosphoric acid impurities. Finally, the cordycepin solution was desalted, concentrated and crystallized using a reverse osmosis membrane (ethanol: water, 2:1, v:v) to obtain 21.3 g of cordycepin (white solid, yield 85%).

[0153] Example 10 Preparation of cordycepin using 3'-adenosine phosphate as raw material using liquid enzymes (CorDep, CorRed) and NADH regenerating enzyme (MspFDH)

[0154]

[0155] Similar to Example 7, 58.6 g of 3'-adenosine disodium salt (150 mM), 3.6 g of reduced nicotinamide adenine dinucleotide disodium salt (NADH, 5 mM), and 11 g of sodium formate (160 mM) were added to 1 L of 100 mM pH 7.5 tris(hydroxymethylaminomethane) hydrochloric acid (Tris.HCl) solution, and then the pH of the reaction solution was adjusted back to 7.5. Finally, 2000 U of CorDep crude enzyme solution, 2000 U of CorRed crude enzyme solution, and 3000 U of MspFDH crude enzyme solution were added to start the reaction. During the reaction, the reaction pH was adjusted between 7.0 and 8.5, and the reaction was completed after 4 hours. The pH value of the reaction solution was adjusted to acidity to terminate the reaction, and then the pH value of the solution was adjusted back to 7.0 and loaded onto D201 anion exchange resin to remove phosphoric acid-containing impurities. Finally, the cordycepin-containing solution was desalted, concentrated and crystallized using a reverse osmosis membrane (ethanol: water, 2:1, v:v) to obtain 34.2 g of cordycepin (white solid, yield 91%).

[0156] Example 11 Preparation of cordycepin using 3'-adenosine phosphate as raw material using liquid enzymes (CorDep, CorRed) and NADH regenerating enzyme (MspFDH)

[0157]

[0158] Similar to Example 8, 58.6 g of 3'-adenosine disodium salt (150 mM), 1.4 g of reduced nicotinamide adenine dinucleotide disodium salt (NADH, 2 mM), and 11 g of sodium formate (160 mM) were added to 1 L of 100 mM pH 7.5 tris(hydroxymethylaminomethane) hydrochloric acid (Tris.HCl) solution, and then the reaction solution was adjusted back to pH 7.5. Finally, 1800 U of CorDep crude enzyme solution, 1500 U of CorRed crude enzyme solution, and 2800 U of SpFDH crude enzyme solution were added to start the reaction. During the reaction, the reaction pH was adjusted between 7.0 and 8.5, and the reaction was completed after 4 hours. The pH value of the reaction solution was adjusted to acidity to terminate the reaction, and then the pH value of the solution was adjusted back to 7.0 and loaded with D201 anion exchange resin to remove phosphoric acid impurities. Finally, the cordycepin solution was desalted, concentrated and crystallized using a reverse osmosis membrane (ethanol: water, 2:1, v:v) to obtain 32.7-35 grams of cordycepin (white solid, yield 87%). Example 12 Preparation of cordycepin using 3'-adenosine phosphate as raw material using liquid enzymes (CorDep, CorRed) and NADH regeneration enzymes (MspFDH)

[0159]

[0160] Similar to Example 9, 58.6 g of 3'-adenosine disodium salt (150 mM), 4.3 g of reduced nicotinamide adenine dinucleotide disodium salt (NADH, 6 mM), and 11 g of sodium formate (160 mM) were added to 1 L of 100 mM pH 7.5 tris(hydroxymethylaminomethane) hydrochloric acid (Tris.HCl) solution, and then the reaction solution was adjusted back to pH 7.5. Finally, 2400 U of CorDep crude enzyme solution, 2200 U of CorRed crude enzyme solution, and 3500 U of SpFDH crude enzyme solution were added to start the reaction. During the reaction, the reaction pH was adjusted between 7.0 and 8.5. The reaction was completed after 4 hours. The pH value of the reaction solution was adjusted to acidity to terminate the reaction, and then the pH value of the solution was adjusted back to 7.0 and loaded with D201 anion exchange resin to remove phosphoric acid-containing impurities. Finally, the cordycepin-containing solution was desalted, concentrated and crystallized using a reverse osmosis membrane (ethanol: water, 2:1, v:v) to obtain 35 g of cordycepin (white solid, yield 93%).

[0161] Example 13 Using adenosine as raw material, cordycepin was prepared by one-pot method using liquid enzymes (Cor3K, CorDep, CorRed) and ATP regenerating enzyme (PcPyK) and NADH regenerating enzyme (MspFDH)

[0162]

[0163] 26.7 g of adenosine (100 mM), 2.1 g of magnesium chloride hexahydrate (10 mM), 1.5 g of potassium chloride (20 mM), 2.8 g of adenosine triphosphate disodium salt (5 mM), 20.9 g of phosphoenolpyruvate (PEP, 110 mM), 3.6 g of reduced nicotinamide adenine dinucleotide disodium salt (NADH, 5 mM), and 7.6 g of sodium formate (110 mM) were added to 1 L of 100 mM pH 8.0 tris-hydroxymethylaminomethane hydrochloric acid (Tris.HCl) solution. The pH value of the solution was adjusted back to pH 8.0. Finally, 1500 U of Cor3K, 2000 U of PcPyK, 1000 U of CorDep, 1000 U of CorRed, and 2000 U of MspFDH enzyme were added successively to start the reaction. The pH value was maintained between 7.0 and 8.5 during the reaction, and the reaction was basically completed after 4 hours. Finally, the reaction solution was adjusted to acidity to terminate the reaction, and then the pH was adjusted back to 7.0 and the phosphoric acid impurities were separated and removed using D201 anion exchange resin. Finally, the cordycepin solution was desalted, concentrated and crystallized using a reverse osmosis membrane (ethanol: water, 2:1, v:v) to obtain 18.3 g of cordycepin (white solid, yield 73%).

[0164] Example 14 Using adenosine as raw material, cordycepin was prepared by one-pot method using liquid enzymes (Cor3K, CorDep, CorRed) and ATP regenerating enzyme (PcPyK) and NADH regenerating enzyme (MspFDH)

[0165]

[0166] 26.7 g of adenosine (100 mM), 2.1 g of magnesium chloride hexahydrate (10 mM), 1.5 g of potassium chloride (20 mM), 1.1 g of adenosine triphosphate disodium salt (2.0 mM), 17.1 g of phosphoenolpyruvate (PEP, 90 mM), 2.2 g of reduced nicotinamide adenine dinucleotide disodium salt (NADH, 3.0 mM), and 7.6 g of sodium formate (110 mM) were added to 1 L of 100 mM pH 8.0 tris-hydroxymethylaminomethane hydrochloric acid (Tris.HCl) solution. The pH value of the solution was adjusted back to pH 8.0. Finally, 1400 U of Cor3K, 1800 U of PcPyK, 800 U of CorDep, 900 U of CorRed, and 1800 U of MspFDH enzyme were added successively to start the reaction. The pH value was maintained between 7.0 and 8.5 during the reaction, and the reaction was basically completed after 4 hours. Finally, the reaction solution was adjusted to acidity to terminate the reaction, and then the pH was adjusted back to 7.0 and the phosphoric acid impurities were separated and removed using D201 anion exchange resin. Finally, the cordycepin solution was desalted, concentrated and crystallized using a reverse osmosis membrane (ethanol: water, 2:1, v:v) to obtain 17.5 g of cordycepin (white solid, yield 70%).

[0167] Example 15 Using adenosine as raw material, cordycepin was prepared by one-pot method using liquid enzymes (Cor3K, CorDep, CorRed) and ATP regenerating enzyme (PcPyK) and NADH regenerating enzyme (MspFDH)

[0168]

[0169] 26.7 g of adenosine (100 mM), 2.1 g of magnesium chloride hexahydrate (10 mM), 1.5 g of potassium chloride (20 mM), 3.4 g of adenosine triphosphate disodium salt (6.0 mM), 24.7 g of phosphoenolpyruvate (PEP, 130 mM), 4.3 g of reduced nicotinamide adenine dinucleotide disodium salt (NADH, 6.0 mM), and 7.6 g of sodium formate (110 mM) were added to 1 L of 100 mM pH 8.0 tris-hydroxymethylaminomethane hydrochloric acid (Tris.HCl) solution. The pH value of the solution was adjusted back to pH 8.0. Finally, 1600 U of Cor3K, 2400 U of PcPyK, 1200 U of CorDep, 1100 U of CorRed, and 2400 U of MspFDH enzyme were added successively to start the reaction. The pH value was maintained between 7.0 and 8.5 during the reaction, and the reaction was basically completed after 4 hours. Finally, the reaction solution was adjusted to acidity to terminate the reaction, and then adjusted back to pH 7.0 and separated and removed by D201 anion exchange resin containing phosphoric acid impurities. Finally, the cordycepin solution was desalted, concentrated and crystallized by reverse osmosis membrane (ethanol: water, 2:1, v:v) to obtain 18.8 g of cordycepin (white solid, yield 75%).

[0170] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. An enzyme mutant, characterized in that The enzymes include one or more of cordycepin kinase (Cor3K), cordycepin dephosphatase (CorDep), cordycepin reductase (CorRed), pyruvate kinase (PcPyK) and / or formate dehydrogenase (MspFDH); The mutation site of the cordycepin kinase (Cor3K) includes one or more of R13A, M14L, W32T, G35F, D63S, G64M, D65Q, R68I, G70M, N72Y, N73K, I89V, Q157T or K180S; The mutation site of the cordycepin dephosphatase (CorDep) includes one or more of K130N, E149D or A175V; The mutation site of the cordycepin reductase (CorRed) includes one or more of S68M, E69G, E70F, R81V, K89S, P92W, F127N, G128I, T133V, R184A, H187T or N198D; The mutation site of the pyruvate kinase (PcPyK) includes one or more of F31I, P99N, G105L, P169M, D248T or W312F; The mutation sites of the formate dehydrogenase (MspFDH) include one or more of P12C, Q35T or Y188L.

2. The enzyme mutant according to claim 1, characterized in that The cordycepin kinase (Cor3K) is derived from Bacteroides thetaiotaomicron (Uniprot ID: Q8AAQ1, EC 2.7.1.25); The cordycepin dephosphatase (CorDep) is derived from Cordyceps militaris (Uniprot ID: G3JF09); The cordycepin reductase (CorRed) is derived from Thermococcus sibiricus (Uniprot ID: C6A1Z0); The pyruvate kinase (PcPyK) is derived from Pyrobaculum calidifontis (Uniprot ID: A3MS52, EC 2.7.1.40); The formate dehydrogenase (MspFDH) is derived from Microbacterium sp.

3. The mutant of the enzyme according to claim 1 or 2, characterized in that The mutants of the enzymes include mutants of cordycepin kinase (Cor3K), mutants of cordycepin dephosphatase (CorDep), mutants of cordycepin reductase (CorRed), mutants of pyruvate kinase (PcPyK) and / or mutants of formate dehydrogenase (MspFDH); Wherein, the mutant of cordycepin kinase (Cor3K) has: (I), the amino acid sequence shown in SEQ ID No.1; (II) an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence described in (I), and having the same function as the amino acid sequence described in (I); or (III), an amino acid sequence having 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or more identity with the amino acid sequence described in (I) or (II); or The mutant of cordycepin dephosphatase (CorDep) has: (I), the amino acid sequence shown in SEQ ID No.2; (II) an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence described in (I), and having the same function as the amino acid sequence described in (I); or (III), an amino acid sequence having 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or more identity with the amino acid sequence described in (I) or (II); or The mutant of cordycepin reductase (CorRed) has: (I), the amino acid sequence shown in SEQ ID No.3; (II) an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence described in (I), and having the same function as the amino acid sequence described in (I); or (III), an amino acid sequence having 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or more identity with the amino acid sequence described in (I) or (II); or The mutant of pyruvate kinase (PcPyK) has: (I), the amino acid sequence shown in SEQ ID No.4; (II) an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence described in (I), and having the same function as the amino acid sequence described in (I); or (III), an amino acid sequence having 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or more identity with the amino acid sequence described in (I) or (II); or The mutant of formate dehydrogenase (MspFDH) has: (I), the amino acid sequence shown in SEQ ID No.5; (II) an amino acid sequence obtained by substituting, deleting or adding one or more amino acids to the amino acid sequence described in (I), and having the same function as the amino acid sequence described in (I); or (III) an amino acid sequence that is 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% or more identical to the amino acid sequence described in (I) or (II).

4. An enzyme composition or an immobilized enzyme thereof, characterized in that: The invention comprises a mutant of the enzyme according to any one of claims 1 to 3.

5. A nucleic acid molecule encoding a mutant of the enzyme according to any one of claims 1 to 3 or an enzyme composition or an immobilized enzyme thereof according to claim 4.

6. The nucleic acid molecule according to claim 5, characterized in that comprising a nucleic acid molecule encoding a mutant of the cordycepin kinase (Cor3K), a nucleic acid molecule encoding a mutant of the cordycepin dephosphatase (CorDep), a nucleic acid molecule encoding a mutant of the cordycepin reductase (CorRed), a nucleic acid molecule encoding a mutant of the pyruvate kinase (PcPyK) and / or a nucleic acid molecule encoding a mutant of the formate dehydrogenase (MspFDH); The nucleic acid molecule encoding the mutant of cordycepin kinase (Cor3K) has: (I), the nucleotide sequence shown in SEQ ID NO.6; or (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or (IV), a nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to any one of (I) to (III); or The nucleic acid molecule encoding the mutant of cordycepin dephosphatase (CorDep) has: (I), the nucleotide sequence shown in SEQ ID NO.7; or (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or (IV), a nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to any one of (I) to (III); or The nucleic acid molecule encoding the mutant of cordycepin reductase (CorRed) has: (I), the nucleotide sequence shown in SEQ ID NO.8; or (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or (IV), a nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to any one of (I) to (III); or The nucleic acid molecule encoding the mutant of pyruvate kinase (PcPyK) has: (I), the nucleotide sequence shown in SEQ ID NO.9; or (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or (IV), a nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to any one of (I) to (III); or The nucleic acid molecule encoding the mutant of formate dehydrogenase (MspFDH) has: (I), the nucleotide sequence shown in SEQ ID NO.10; or (II) a nucleotide sequence that encodes the same protein as the nucleotide sequence shown in (I) but is different from the nucleotide sequence shown in (I) due to the degeneracy of the genetic code; or (III) a nucleotide sequence obtained by replacing, deleting or adding one or more nucleotide sequences to the nucleotide sequence shown in (I) or (II), and having the same or similar function as the nucleotide sequence shown in (I) or (II); or (IV) A nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to any one of the nucleotide sequences of (I) to (III).

7. An expression vector or host, characterized in that The expression vector comprises the nucleic acid molecule according to claim 5 or 6; The host is transfected or transformed with the expression vector.

8. Use of any of the following in the preparation of cordycepin; (I) A mutant of the enzyme according to any one of claims 1 to 3; (II), the enzyme composition or the immobilized enzyme thereof as claimed in claim 4; (III), a nucleic acid molecule according to claim 5 or 6; or (IV) The expression vector or host according to claim 7.

9. A method for preparing cordycepin, characterized in that: Cordycepin can be obtained by using adenosine as raw material and converting it into any of the following: (I) A mutant of the enzyme according to any one of claims 1 to 3; (II), the enzyme composition or the immobilized enzyme thereof as claimed in claim 4; (III), a nucleic acid molecule according to claim 5 or 6; or (IV) The expression vector or host according to claim 7.

10. The preparation method according to claim 9, characterized in that: Adenosine is used as a starting material, 3'-adenosine phosphate (3'-AMP) is generated by the mutant of cordycepin kinase (Cor3K), dehydrated adenosine is generated by the mutant of cordycepin dephosphatase (CorDep), and cordycepin is finally generated by the mutant of cordycepin reductase (CorRed); The enzyme activity of the mutant of cordycepin kinase (Cor3K) is 800-1500, 1200-2000 U or 1400-1600 U; or The enzymatic activity of the mutant of cordycepin dephosphatase (CorDep) is 1200-1800U, 1800-2400U or 800-1200U; or The enzyme activity of the mutant of cordycepin reductase (CorRed) is 800-1200U, 1500-2200U or 900-1100U; or The enzyme activity of the mutant of pyruvate kinase (PcPyK) is 1800-3000U or 1800-2400U; or The enzyme activity of the mutant of formate dehydrogenase (MspFDH) is 2800-3500 or 1800-2400U.

Citation Information

Patent Citations

  • Interferon gamma conjugates

    CN101172160A

  • Preparation method of D-ribulose by immobilized enzyme catalysis

    CN110452942A

  • Mutant composition, fusion enzyme and collagen tripeptide preparation method

    CN115820578A

  • Beta-alanine ligase mutant and application thereof

    CN116445429A

  • Yeast engineering bacteria for high-yield cordycepin as well as construction method and application thereof

    CN118291291A